Accelerating Clinical Trials Evaluating Disease-Modifying Therapies For T1D
Funding Amount
Not stated
Deadline
Deadline not published
Grant Type
Foundation
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Other requirements
- _ You can learn more about this opportunity by visiting the funder's [website](https://www.breakthrought1d.org/wp-content/uploads/2024/08/FY25-RFA-Clinical-Advancement-of-DMTs-FINAL.pdf).
Overview
Accelerating Clinical Trials Evaluating Disease-Modifying Therapies For T1D
Letters of intent (LOI’s) are sought from academic and/or industry applicants for clinical trials to evaluate drugs and biologics to delay, halt, or reverse T1D through supporting or expanding endogenous beta cell survival and function, disrupting autoimmune pathobiology, or combinations of the above.
Breakthrough T1D is requesting applications that propose Proof of Concept (POC) human subject research trials to provide the data necessary to enable further clinical development, and Phase 1 or 2 trials to determine safety and efficacy. Trials should be powered for the stage of clinical development proposed and include the appropriate and justified endpoints. Phase 3 trials may be considered, however, approval must be obtained from the scientific contact below prior to submission of an LOI so that the budgetary and timeline needs of the trial can be assessed.
Eligibility
_ You can learn more about this opportunity by visiting the funder's website.
What Breakthrough T1D actually gave
Source: IRS Form 990, 2025
- Grants in 2025
- 100
- Total given
- $79.32M
- Median grant
- $378K
- Range
- $25K–$7.28M
- By dollars: Massachusetts 21%, California 13%, Florida 7%. Top recipient cities: Boston, MA; New York, NY; Seattle, WA.
- 0% of grants with a stated purpose were for general or operating support.
- 16% of recipients were new grantees, not repeat recipients.
Example grants
University of Massachusetts Medical School · Worcester, MA
T1d research
$7.28M
The Regents of the University of California San Francisco · San Francisco, CA
T1d research
$5.4M
The University of Chicago · Chicago, IL
T1d research
$4.12M
Regents of the University of Colorado · Denver, CO
T1d research
$3.58M
University of Florida · Gainesville, FL
T1d research
$3.13M
Focus Areas & Funding Uses
Fields of Work
- Science research
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
RFA- Advancing Genetic Risk Assessment for Type 1 Diabetes: Improving Prediction and Clinical Translation Grant
Breakthrough T1D
Amount
Up to US $900,000
Deadline
Deadline not published
Breakthrough T1D- Innovative Awards Grant
Breakthrough T1D
Amount
Up to US $200,000
Deadline
Deadline not published
Pilot Projects to Enhance the Human Virome Program (R03 Clinical Trials Not Allowed)
National Institutes of Health
Amount
$50,000 - $100,000
Deadline
November 10, 2026
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
National Institutes of Health
Amount
$40,000,000 total
Deadline
November 10, 2026
DoW Vision, Clinical Trial Award
Defense Health Agency Contracting Activity - DHACA
Amount
$2,600,000 total
Deadline
November 12, 2026
DoW Toxic Exposures Clinical Trial Award
Defense Health Agency Contracting Activity - DHACA
Amount
$4,500,000 total
Deadline
November 19, 2026
Ready to apply for Accelerating Clinical Trials Evaluating Disease-Modifying Therapies For T1D?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Accelerating Clinical Trials Evaluating Disease-Modifying Therapies For T1D. Now let's win it.